# SomaLogic

SomaLogic is a Biotechnology based in Boulder, United States.

## Overview

- **Organization type:** Biotechnology
- **Headquarters:** Boulder, United States
- **Region:** Europe
- **Address:** Boulder, CO, United States
- **Founded:** 2000
- **Assets under management:** Undisclosed
- **Website:** somalogic.com
- **LinkedIn:** https://www.linkedin.com/company/somalogic

## Regulatory record

- **Reports private funds:** No

## About

SomaLogic is a company based in Boulder, Colorado, founded in 1999. It provides high-throughput proteomics services to academic institutions, pharmaceuticals, and biotechnology companies. SomaLogic offers the SomaScan Assay and was acquired by Illumina in January 2026 for $350M–$425M.

## Sectors

- Digital Health
- Healthcare Services
- AI/ML

## Offices

- Basel, Switzerland

## People

- Adam Taich — Chief Executive Officer
- Larry Gold — Founder

## Questions

### Who runs investment decisions at SomaLogic?

Adam Taich has been CEO since 2022, succeeding founder Larry Gold. The firm is a publicly traded biotechnology company, so investment decisions — such as capital allocation and R&D spending — are made by management and approved by its board of directors. No family office or wealth management structure exists.

### How does SomaLogic source proprietary deal flow?

SomaLogic generates revenue through partnerships and service agreements with pharmaceutical companies, academic institutions, and biobanks. Its proprietary SomaScan platform serves as the core offering, and the firm actively pursues collaborations to integrate the assay into large-scale clinical trials and population-health studies.

### Does SomaLogic participate in fund commitments or only direct deals?

SomaLogic does not participate in fund commitments or direct investments. Its business model is based on licensing and service fees from its proteomics platform. The firm is not an investment vehicle.

### What investment stages does SomaLogic typically target?

SomaLogic does not target investment stages. The company's focus is on R&D and commercialization of its SomaScan assay. It engages with partners at various stages of drug development, from preclinical research to Phase III trials.

### Which sectors does SomaLogic explicitly avoid?

SomaLogic's platform is broadly applicable across therapeutic areas, but publicly disclosed partnerships focus on cardiometabolic diseases, oncology, and neuroscience. No explicit sector avoidance is documented.

## Related profiles

- [Teralytics AG](https://altss.com/profile/teralytics-ag)
- [Runyon Group](https://altss.com/profile/runyon-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/somalogic

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology